Novavax Inc (NVAX NASDAQ) stock market data APIs
$8.1181
0.08(1%)
as of October 17, 2025
Try our APIs with
free plan!
Novavax Inc Financial Data Overview
Price chart is built with
Anychart
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Prev. Close
8.1181
Open
8.1966
High
8.4024
Low
8.0957
52 wk Range
5.01-11.55
Market Cap
1 316 M
P/E Ratio
3.6486
Shares Outstanding
162 M
Revenue
1 079 M
EPS
0.62
Beta
2.746
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novavax Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novavax Inc data using free add-ons & libraries
Get Novavax Inc Fundamental Data
Novavax Inc Fundamental data includes:
- Net Revenue: 1 079 M
- EBITDA: 408 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novavax Inc News
New
Sector Update: Health Care Stocks Higher Tuesday Afternoon
Health care stocks edged higher Tuesday afternoon, with the NYSE Health Care Index and the Health Ca PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Top Novavax Shareholder Demands Company’s Sale
Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should sell itself. Continue Reading View Comments
Novavax shareholder with large stake asks company to consider selling itself
[Germany Begins Novavax Covid Vaccinations] Carsten Koall * Shah Capital Management, which has a 7.2% stake in vaccine maker Novavax (NASDAQ:NVAX [https://seekingalpha.com/symbol/NVAX]), is calling...
AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving AstraZeneca ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
